U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21FN6O.C6H8O7
Molecular Weight 536.5102
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIVAVOTINIB CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1C=C(C=N1)C2=C3C(=O)NCC3=C(F)C(N[C@@H]4CCCC[C@@H]4N)=N2

InChI

InChIKey=ZVPYVZMKBQYKQG-ZVWHLABXSA-N
InChI=1S/C17H21FN6O.C6H8O7/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19;7-3(8)1-6(13,5(11)12)2-4(9)10/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,12+;/m0./s1

HIDE SMILES / InChI
TAK-659 is an investigational, reversible, and potent dual inhibitor of SYK and FLT-3 kinases. TAK-659 inhibited the pro-survival, proliferative, chemoresistant, and activation effects promoted by the microenvironment. Combination of TAK-659 with other BCR inhibitors showed a synergistic effect in inducing apoptosis. Combination of TAK-659 and ibrutinib induced significantly higher cytotoxicity toward CLL cells. TAK-659 suppressed splenomegaly and tumor development in an LMP2A/Myc mouse model in nanomolar concentrations. In addition, TAK-659 also blocked metastasis of tumor cells into bone marrow. A phase Ib/II study of TAK-659 is underway in patients with relapsed or refractory acute myelogenous leukemia

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P43405
Gene ID: 6850.0
Gene Symbol: SYK
Target Organism: Homo sapiens (Human)
3.2 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Syk inhibitors in clinical development for hematological malignancies.
2017 Jul 28

Sample Use Guides

During the phase Ib dose escalation study, adult pts with R/R AML received oral TAK-659 daily at doses of 60, 100, 120, and 160 mg.
Route of Administration: Oral
Name Type Language
MIVAVOTINIB CITRATE
USAN  
Official Name English
3H-PYRROLO(3,4-C)PYRIDIN-3-ONE, 6-(((1R,2S)-2-AMINOCYCLOHEXYL)AMINO)-7-FLUORO-1,2-DIHYDRO-4-(1-METHYL-1H-PYRAZOL-4-YL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Systematic Name English
6-[[(1R,2S)-2-Aminocyclohexyl]amino]-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-3H-pyrrolo[3,4-c]pyridin-3-one, 2-hydroxypropane-1,2,3-tricarboxylate (1:1)
Systematic Name English
6-(((1R,2S)-2-AMINOCYCLOHEXYL)AMINO)-7-FLUORO-4-(1-METHYL-1H-PYRAZOL-4-YL)-1,2-DIHYDRO-3H-PYRROLO(3,4-C)PYRIDIN-3-ONE MONOCITRATE
Systematic Name English
TAK-659
Code English
MIVAVOTINIB CITRATE [USAN]
Common Name English
6-(((1R,2S)-2-AMINOCYCLOHEXYL)AMINO)-7-FLUORO-4-(1-METHYL-1H-PYRAZOL-4-YL)-1,2-DIHYDRO-3H-PYRROLO(3,4-C)PYRIDINE-3-ONE MONOCITRATE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 671718
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
EU-Orphan Drug EU/3/18/1974
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
FDA ORPHAN DRUG 606817
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
FDA ORPHAN DRUG 556916
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL3544931
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
USAN
HI-54
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
SMS_ID
100000177400
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
NCI_THESAURUS
C188286
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
CAS
1952251-25-0
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
FDA UNII
6ZJ8V3Q0H1
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY
PUBCHEM
118980937
Created by admin on Sat Dec 16 18:27:39 GMT 2023 , Edited by admin on Sat Dec 16 18:27:39 GMT 2023
PRIMARY